image
Healthcare - Biotechnology - NASDAQ - US
$ 3.55
14.4 %
$ 187 M
Market Cap
-0.97
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one KOD stock under the worst case scenario is HIDDEN Compared to the current market price of 3.55 USD, Kodiak Sciences Inc. is HIDDEN

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one KOD stock under the base case scenario is HIDDEN Compared to the current market price of 3.55 USD, Kodiak Sciences Inc. is HIDDEN

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one KOD stock under the best case scenario is HIDDEN Compared to the current market price of 3.55 USD, Kodiak Sciences Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart KOD

image
$11.0$11.0$10.0$10.0$9.0$9.0$8.0$8.0$7.0$7.0$6.0$6.0$5.0$5.0$4.0$4.0$3.0$3.0$2.0$2.0Nov '24Nov '2415 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 Apr
FINANCIALS
0 REVENUE
0.00%
-187 M OPERATING INCOME
32.62%
-176 M NET INCOME
32.36%
-117 M OPERATING CASH FLOW
23.91%
-755 K INVESTING CASH FLOW
-0.30%
501 K FINANCING CASH FLOW
1516.13%
0 REVENUE
0.00%
-46.2 M OPERATING INCOME
0.97%
-44.1 M NET INCOME
-0.36%
-30.1 M OPERATING CASH FLOW
-42.13%
-124 K INVESTING CASH FLOW
39.51%
404 K FINANCING CASH FLOW
0.00%
Balance Sheet Kodiak Sciences Inc.
image
Current Assets 172 M
Cash & Short-Term Investments 168 M
Receivables 0
Other Current Assets 3.86 M
Non-Current Assets 164 M
Long-Term Investments 0
PP&E 149 M
Other Non-Current Assets 14.9 M
50.08 %44.32 %4.44 %Total Assets$335.6m
Current Liabilities 25.6 M
Accounts Payable 3.92 M
Short-Term Debt 10.6 M
Other Current Liabilities 11 M
Non-Current Liabilities 160 M
Long-Term Debt 59.7 M
Other Non-Current Liabilities 100 M
5.74 %5.95 %32.23 %53.97 %Total Liabilities$185.3m
EFFICIENCY
Earnings Waterfall Kodiak Sciences Inc.
image
Revenue 0
Cost Of Revenue 0
Gross Profit 0
Operating Expenses 187 M
Operating Income -187 M
Other Expenses -10.6 M
Net Income -176 M
00(20m)(20m)(40m)(40m)(60m)(60m)(80m)(80m)(100m)(100m)(120m)(120m)(140m)(140m)(160m)(160m)(180m)(180m)(200m)(200m)000(187m)(187m)11m(176m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
0.00% GROSS MARGIN
0.00%
0.00% OPERATING MARGIN
0.00%
0.00% NET MARGIN
0.00%
-117.25% ROE
-117.25%
-52.51% ROA
-52.51%
-58.28% ROIC
-58.28%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Kodiak Sciences Inc.
image
00(50m)(50m)(100m)(100m)(150m)(150m)(200m)(200m)(250m)(250m)(300m)(300m)201720172018201820192019202020202021202120222022202320232024202420252025
Net Income -176 M
Depreciation & Amortization 0
Capital Expenditures -400 K
Stock-Based Compensation 60.2 M
Change in Working Capital 0
Others -20 M
Free Cash Flow -118 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Kodiak Sciences Inc.
image
Wall Street analysts predict an average 1-year price target for KOD of $10.4 , with forecasts ranging from a low of $2 to a high of $20 .
KOD Lowest Price Target Wall Street Target
2 USD -43.66%
KOD Average Price Target Wall Street Target
10.4 USD 193.76%
KOD Highest Price Target Wall Street Target
20 USD 463.38%
Price
Max Price Target
Min Price Target
Average Price Target
20201818161614141212101088664422Jun '24Jun '24Jul '24Jul '24Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 18
6. Ownership
Insider Ownership Kodiak Sciences Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
12.5 K USD 1
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Down -28.08% in 4 Weeks, Here's Why You Should You Buy the Dip in Kodiak Sciences (KOD) Kodiak Sciences (KOD) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock. zacks.com - 1 month ago
Kodiak Q4 Loss Narrower Than Expected, Pipeline Development in Focus KOD reports a narrower-than-expected loss for the fourth quarter of 2024. The company provides updates regarding its pipeline development plans. zacks.com - 1 month ago
Kodiak Sciences Announces Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results PALO ALTO, Calif. , March 27, 2025 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), today reported recent business highlights and financial results for the fourth quarter and full year ended December 31, 2024. prnewswire.com - 1 month ago
Kodiak Sciences Completes Enrollment in Second Registrational Trial of Tarcocimab in Patients with Diabetic Retinopathy Topline clinical data of the confirmatory registrational study GLOW2 expected in 1Q 2026. GLOW2 study design mirrors GLOW1 study, which met primary endpoint and all key secondary endpoints with high statistical significance PALO ALTO, Calif. prnewswire.com - 1 month ago
Kodiak Sciences: Anti-VEGF Could Win Nicely On Retinal Disorders Kodiak Sciences basically uses a novel biopolymer conjugate platform to develop more durable, next-generation retinal disease therapies. Today, KOD's pipeline includes Phase 3 candidates for DR, RVO, and wet AMD, targeting an $18 billion TAM by 2028. The main catalyst to watch now is their upcoming pivotal data in 2026 that could lead to FDA approval by 2027. seekingalpha.com - 2 months ago
Kodiak Sciences to Present at Glaucoma 360 New Horizons Forum 2025 PALO ALTO, Calif. , Feb. 4, 2025 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat a broad spectrum of retinal diseases, announced today that senior management will present the Company's pipeline program exploring the treatment of glaucoma at the Glaucoma 360 New Horizons Forum 2025 on Friday, February 7, 2025, in San Francisco, CA. prnewswire.com - 2 months ago
Kodiak Sciences to Present at 43rd Annual J.P. Morgan Healthcare Conference PALO ALTO, Calif. , Jan. 7, 2025 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat a broad spectrum of retinal diseases, announced today that Victor Perlroth, M.D. prnewswire.com - 3 months ago
KOD Stock Rallies 271% in 6 Months on Eye Disease Program Updates Kodiak stock skyrockets 271% in six months on the back of positive updates from the tarcocimab program for treating retinal vascular diseases. zacks.com - 3 months ago
What Awaits These 4 Biotech Stocks That More Than Doubled in 2024 Here are four drug and biotech stocks, ARQT, MESO, MNPR and KOD, which have more than doubled in 2024 with room for further growth in 2025. zacks.com - 4 months ago
KOD Stock Up as Jefferies Upgrades Rating on Huge Pipeline Potential Kodiak stock surges as Jefferies upgrades it to a "BUY" rating based on the significant potential of its pipeline candidates for retinal disease indications. zacks.com - 4 months ago
Eye-Disease Focused Kodiak Sciences Is A Promising 'Turnaround Story For 2025': Analyst Upgrades Stock Jefferies has upgraded Kodiak Sciences Inc. KOD, a biopharmaceutical company focused on retinal (eye) diseases. benzinga.com - 4 months ago
Kodiak Sciences Inc. (KOD) Just Flashed Golden Cross Signal: Do You Buy? Kodiak Sciences Inc. (KOD) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, KOD's 50-day simple moving average crossed above its 200-day simple moving average, known as a "golden cross. zacks.com - 5 months ago
8. Profile Summary

Kodiak Sciences Inc. KOD

image
COUNTRY US
INDUSTRY Biotechnology
MARKET CAP $ 187 M
Dividend Yield 0.00%
Description Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is KSI-301, an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate to treat retinal diseases with an inflammatory component; and KSI-601, a triplet inhibitor for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.
Contact 1200 Page Mill Road, Palo Alto, CA, 94304 https://kodiak.com
IPO Date Oct. 4, 2018
Employees 109
Officers Ms. Tracy Chien Vice President & Corporate Controller Dr. Victor Perlroth M.D. Co-Founder, Chairman, Chief Executive Officer & President Dr. Dolly S. Chang M.D., M.P.H., Ph.D. Chief Scientific Officer Dr. J. Pablo Velazquez-Martin M.D. Chief Medical Officer Mr. John A. Borgeson CPA, M.B.A. Executive Vice President, Chief Financial Officer & Secretary Ms. Almas Qudrat M.Sc. Chief Quality Officer Dr. Hong Liang Ph.D. Senior Vice President of Development Dr. Stephen Raillard Ph.D. Senior Vice President of Chemical Development & Manufacturing